Food Frontiers, Volume 7, Issue 3, May 2026.ABSTRACT Ergothioneine (EGT), a natural thiol derivative, has gained attention as a geroprotective nutraceutical. Preclinical research shows EGT scavenges free radicals, maintains mitochondrial integrity, slows telomere erosion, and regulates proteostasis via autophagy and senescent cell clearance.
Tian‐Tian Tian +3 more
wiley +1 more source
Poly (ADP-ribose) polymerase inhibitors in cancer therapy. [PDF]
Chin Med J (Engl)Zhu Z, Shi Y.
europepmc +1 more source
Homoisoflavonoids—From Natural Specificity and Biosynthesis to Precision Health‐Promoting Mechanisms
Food Frontiers, Volume 7, Issue 3, May 2026.Homoisoflavonoids are rare flavonoids with a unique bi‐aromatic oxygen‐heterocyclic structure. This review synthesizes their structure–activity relationships in anti‐inflammatory, hypoglycemic, and anticancer contexts. By highlighting their specific natural distribution and outlining biosynthetic pathways, it provides a conceptual framework and ...
Jing Zhang +4 more
wiley +1 more source
Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors. [PDF]
Curr Breast Cancer RepRay A, Opyrchal M.
europepmc +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang +4 more
wiley +1 more source
Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia. [PDF]
J Atheroscler ThrombXie JJ +9 more
europepmc +1 more source
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.Abstract Niraparib is a poly(ADP‐ribose) polymerase inhibitor approved for maintenance treatment of advanced ovarian cancer. Using data from a previous niraparib population pharmacokinetic (PK) model with data from four studies, this model added phase 1 pharmacokinetic data from two studies.
Anna Gaffney +4 more
wiley +1 more source
Progesterone Enhances the Sensitivity of Ovarian Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Suggesting a Role for Transcription-Replication Conflict-Related Pathways: An In Vitro Study. [PDF]
CureusSuizu E +8 more
europepmc +1 more source
Journal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.ABSTRACT Extracellular vesicles (EVs), including exosomes, circulate in body fluids and carry pathological genomic information. High‐grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, characterized predominantly by copy number variations (CNVs).
Ryosuke Uekusa +17 more
wiley +1 more source
Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis. [PDF]
J Mol Med (Berl)Lin CY +8 more
europepmc +1 more source